Yoshiya Tanaka
Yoshiya Tanaka is an expert in Rheumatology at University of Occupational and Environmental Health Japan (Japan). As of October 2026, ScienceLeadR ranks Yoshiya Tanaka in the top 1% of experts worldwide for Autoimmune Diseases and Arthritis, and in the top 1% of experts in Japan for Bone Diseases, Metabolic. Yoshiya Tanaka has authored 1,394 publications, the most recent in 2026, and is an investigator in 67 clinical trials, 1 of them ongoing. SLR score: 5,653 (community average: 125). How the SLR is computed.
LeadR Profile
Rheumatology
Subspecialties: Immunology - Internal Medicine - Dermatology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Yoshiya Tanaka, MD, PhD, MACR is Distinguished Professor of the Department of Molecular Targeted Therapeutics, School of Medicine, University of Occupational and Environmental Health, Japan (2025-present). He was Professor and Chairman of the First Department of Internal Medicine (2000-2025) and Dean of Graduate School of Medical Science (2017-2024) of the University. His scientific focus lies on pathological mechanisms and development of novel molecular targeted therapies and treatment strategies in systemic autoimmune diseases. His extensive research portfolio includes over 1,110 peer-reviewed publications in English, with a total impact factor exceeding 6,643 and an h-index of 117. He is the president of JCR (Japan College of Rheumatology), president of JSCI (Japan Society of Clinical Immunology), president of APLAR 2025 and board member of many societies. He is also an associate editor of Arthritis & Rheumatology, RMD Open, Rheumatology, Cytokine, AR&T, IJRD and many, an emeritus editor of MRCR, and an editorial board member of ARD, MR, etc. He has received numerous awards from JSBMR, JCR and EULAR, including honorary award from EULAR in 2023 and ACR Master of Clinical Rheumatology in 2025.
Organizations
Career arc: 1998 - 2026
Number : 1394
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Treatment persistence and clinical outcomes following subcutaneous methotrexate initiation in patients with rheumatoid arthritis: a real-world observational study. PMID 42891641 — safety, arthritis, rheumatic diseases, arthritis, rheumatoid, therapeutics, retention, psychology, methotrexate | Mod Rheumatol | 2026 | 0 |
| Initial treatment strategies and outcomes across haemodynamic thresholds and risk stratification in incident systemic sclerosis-associated pulmonary arterial hypertension: a EUSTAR analysis. PMID 42876376 — sclerosis, hypertension, mortality, arthritis, pulmonary arterial hypertension, therapeutics, scleroderma, systemic | Arthritis Rheumatol | 2026 | 0 |
| Zero Time-to-Echo Imaging of the Hand and Wrist in Rheumatoid Arthritis Patients. PMID 42426952 — radiologists, arthritis, magnetic resonance imaging, radiography, arthritis, rheumatoid, sensitivity and specificity | J Magn Reson Imaging | 2026 | 1 |
| Phenotype-specific associations of mosaic chromosomal alterations in systemic sclerosis. PMID 42425799 — sclerosis, phenotype, rheumatic diseases, scleroderma, systemic, loss of heterozygosity | Ann Rheum Dis | 2026 | 0 |
| Effectiveness of oral anticoagulants in precapillary pulmonary hypertension associated with systemic sclerosis: a EUSTAR cohort study. PMID 42758145 — sclerosis, hypertension, anticoagulants, hypertension, pulmonary, cohort studies, propensity score, rheumatic diseases, therapeutics, scleroderma, systemic | Rheumatology (Oxford) | 2026 | 0 |
Clinical Studies 67
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 9
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Phase 3 Study of Obexelimab in Patients With IgG4 Related Disease NCT05662241 — cells, safety, immunoglobulin g4-related disease, immunoglobulins, antibodies, monoclonal, b-lymphocytes | Phase 3 | Active not recruiting | 2023 |
LeadR Networks
Main global connection map